GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

dazukibart   Click here for help

GtoPdb Ligand ID: 14524

Synonyms: PF-06823859 | PF06823859
Immunopharmacology Ligand
Compound class: Antibody
Comment: Dazukibart (PF-06823859) is a humanized monoclonal antibody that selectively neutralises interferon-beta (IFN-β) and blocks signalling via interferon receptors (IFNAR) [1]. Peptide sequences for the heavy and light chains of dazukibart are claimed as components of antibody CTI-AF1 in Pfizer's patent US10829553 [2].
No information available.
Summary of Clinical Use Click here for help
Dazukibart (PF-06823859) was progressed as a clinical candidate for the treatment of multisystem autoimmune conditions.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03181893 A Study In Adults With Moderate To Severe Dermatomyositis Phase 2 Interventional Pfizer 1
NCT05879718 A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms. Phase 2 Interventional Pfizer
NCT05895786 A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)] Phase 3 Interventional Pfizer
NCT02766621 Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of Compound PF-06823859 Phase 1 Interventional Pfizer First-in-human study to evaluate safety, tolerability, and pharmacokinetics of PF-06823859 in healthy subjects. 3